CAMBRIDGE, Mass., Nov. 01, 2017 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc., a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced the pricing of its initial public offering of 5,500,000 shares of its common stock at a public offering price of $14.00 per share, before underwriting discounts and commissions. Spero Therapeutics, Inc.’s shares are expected to begin trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO.” All of the shares are being offered by Spero Therapeutics, Inc. In addition, Spero Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to 825,000 additional common shares at the initial public offering price. The offering is expected to close on November 6, 2017, subject to the satisfaction of customary closing conditions.

BofA Merrill Lynch, Cowen and Stifel are serving as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as a co-manager for the proposed offering.

About Spero

Spero Therapeutics is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.